Human hIEC Model Reports High Accuracy for Detecting Drug-Induced Intestinal Barrier Damage

The report describes a stem-cell–derived hIEC model designed to detect drug-induced intestinal barrier impairment by recreating key aspects of gut barrier function in vitro. It is presented as a laboratory system for observing functional barrier changes that may be missed when assays focus on overt cytotoxicity alone.

The model is derived from human pluripotent stem cells and differentiates into multiple intestinal cell types, including nutrient-absorbing epithelial cells and mucus-secreting cells, as examples of the intended cellular diversity. To benchmark barrier recreation, the authors report transepithelial electrical resistance (TEER) values closer to the physiological intestinal range (50–100 Ω·cm²) than those observed in Caco-2 models, using this range as a physiologic point of reference for barrier integrity under laboratory conditions. The described cellular composition and TEER benchmark are presented as the basis for representing intestinal barrier function in the model.

Validation is described as testing the platform with a panel of 17 clinically relevant drugs spanning three pharmacological classes: cell cycle inhibitors, tyrosine kinase inhibitors (TKIs), and nonsteroidal anti-inflammatory drugs (NSAIDs). Using a ≥50% TEER reduction cutoff to classify moderate/high versus low GI toxicity, the authors report 94% overall accuracy, 100% specificity, and 92% sensitivity. These metrics are framed as reflecting prediction of clinically observed gastrointestinal toxicity within their evaluation framework.

One example highlighted is the reported detection of barrier disruption with anticancer drugs such as paclitaxel, where the platform detected TEER reductions in cases in which ATP-based viability assays did not show significant cytotoxicity at the same concentrations. The comparison is described as conventional viability assays failing to capture barrier dysfunction despite preserved ATP-based viability readouts within that window. The example is used to illustrate the reported difference between barrier-function–focused readouts and cell-survival–only assays.

Transcriptomic analysis is described as showing downregulation of cytoskeleton-related pathways, cell adhesion molecules, and extracellular matrix–receptor interaction pathways with representative chemotherapeutics (paclitaxel and docetaxel), which the authors link to impaired barrier integrity.

In the narrative provided, downregulation of these gene sets is presented as consistent with destabilization of cellular structure and intercellular connections that support epithelial barrier function.

Together, the molecular findings and functional TEER data are framed as supporting the model’s translational utility for predicting drug-induced GI toxicity.

Key Takeaways:

• The report describes a stem-cell–derived hIEC system containing multiple intestinal cell types (including nutrient-absorbing epithelial cells and mucus-secreting cells) and TEER values closer to the physiological intestinal range than Caco-2 models, serving as a barrier benchmark.
• Across a panel of 17 clinically relevant drugs (cell cycle inhibitors, TKIs, and NSAIDs), the authors report 94% overall accuracy, 100% specificity, and 92% sensitivity using a ≥50% TEER reduction threshold to classify GI toxicity risk.
• Transcriptomics shows downregulation of cytoskeleton-, adhesion-, and ECM-related pathways after taxane exposure, consistent with barrier impairment detected functionally by TEER measurements.